`Petitioner
`
`v.
`
`Genexa Inc.,
`Patent Owner
`
`PGR2023-00051
`Patent 11,617,795
`Patent Owner’s Demonstratives
`
`Oral Argument
`December 12, 2024
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`1
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Overview of Patent Owner’s Argument
`
`Introduction and Background
`I.
`II. Level of Skill
`III. Claim Construction
`IV. Legal Standards
`V. Material Errors in the Petition
`VI. Ground 1 Fails To Demonstrate Obviousness of Claims 1-24
`VII. Ground 2 Fails to Demonstrate Obviousness of Claims 1-17
`VIII.Ground 3 is moot
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`2
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Introduction and Background
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`3
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The ’795 Patent
`
`-Ex.1001, 1:30-35
`
`Ex.1001
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.1001, 2:12-27
`
`-POR, 8-10
`4
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Oral Pharmaceutical Suspensions: Viscosity 1,500-4,000 cP
`
`-Ex.2021, 8:17-21; see also Ex.2009, ¶51; POR at 6-7
`
`Ex.2021
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR at 6-7
`
`5
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Commercially-Available Analgesic Oral Formulations: >1,500 cP
`
`-Ex.2021, Abstract
`
`Ex.2020
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`6
`
`-Ex.2020, 359; see also Ex.2009, ¶52; POR at 7
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The ’795 Patent: Claims Reciting Viscosity
`
`Ex.1001
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.1001, claims 1-4, 7, 15, 18-19; see also POR, 8-10
`7
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Grounds
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.1001, claims 1-4, 7, 15, 18-19
`8
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Level of Skill in the Art
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`9
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Level of Skill
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 6-7; see also POR at 10-12; Ex. 2009, 19-23
`10
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Claim Construction
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`11
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Board Construes Only Those Terms Necessary for Resolution
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 7
`12
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Patent Owner’s Position Regarding Claim Construction
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 12
`13
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`“Agave Syrup”
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 13; see also Ex.2009, ¶¶106-108
`14
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Board Need Not Construe “palatable,” “stable,” or “consisting essentially of”
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 68; see also see also Ex.2009, ¶¶180-182
`15
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Board Construes Only Those Terms Necessary for Resolution
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 17-18
`16
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Legal Standards
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`17
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Burden for Unpatentability and Particularity
`
`“[T]he petitioner has the burden from the onset to show with particularity why the patent it challenges
`is unpatentable. See 35 U.S.C. § 312(a)(3) (requiring IPR petitions to identify ‘with particularity... the
`evidence that supports the grounds for the challenge to each claim’).”
`—Harmonic Inc. v. Avid Tech., Inc., 815 F.3d 1356, 1363 (Fed. Cir. 2016);
`see also 35 U.S.C. § 322(a)(3) (Petitions in post-grant review)
`
`“It is of the utmost importance that petitioners in the IPR proceedings adhere to the requirement that
`the initial petition identify ‘with particularity’ the ‘evidence that supports the grounds for the challenge
`to each claim.’ 35 U.S.C. § 312(a)(3). . . [T]he expedited nature of IPRs bring with it an obligation for
`petitioners to make their case in their petition to institute. While the Board’s requirements are strict
`ones, they are requirements of which petitioners are aware when they seek to institute an IPR.”
`—Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd., 821 F.3d 1359, 1369 (Fed. Cir. 2016)
`
`•
`
`•
`
`•
`
`“[T]he petitioner’s petition, not the Director’s discretion, is supposed to guide the life of the litigation.”
`—SAS Institute, Inc. v. Iancu, 138 S. Ct. 1348, 1356 (2018)
`18
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner Cannot Carry Burden with Conclusory Statements
`
`•
`
`•
`
`“In an inter partes review, the burden of persuasion is on the petitioner to prove ‘unpatentability by a
`preponderance of the evidence,’ 35 U.S.C. § 316(e), and that burden never shifts to the patentee.”
`—Dynamic Drinkware, LLC v. Nat'l Graphics, Inc., 800 F.3d 1375, 1378 (Fed. Cir. 2015);
`see also 35 U.S.C. § 326(e) (Conduct of post-grant review)
`
`Petitioner cannot satisfy its burden of proving obviousness by “mere conclusory statements,” but
`“must instead articulate specific reasoning, based on evidence of record, to support the legal
`conclusion of obviousness.”
`
`—In re Magnum Oil Tools Int’l, Ltd., 829 F.3d 1364, 1380 (Fed. Cir. 2016)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`19
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Obviousness must address the claims “as a whole”
`
`•
`
`•
`
`“The determination of obviousness is made with respect to the subject matter as a whole, not
`separate pieces of the claim.”
`
`—Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075, 1086 (Fed. Cir. 2008)
`
`“The ‘as a whole’ instruction in title 35 prevents evaluation of the invention part by part. Without this
`important requirement, an obviousness assessment might break an invention into its component
`parts (A + B + C), then find a prior art reference containing A, another containing B, and another
`containing C, and on that basis alone declare the invention obvious. . . . . Section 103 precludes this
`hindsight discounting of the value of new combinations by requiring assessment of the invention as a
`whole. ”
`
`—Ruiz v. A.B. Chance Co., 357 F.3d 1270, 1275 (Fed. Cir. 2004)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`20
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Material Errors in the Petition
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`21
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup Does Not Have an Inherent
`Viscosity of 212 cP
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`22
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition Fails Because It Relied on an Unsubstantiated and Incorrect Viscosity
`Value for Agave Syrup
`• Petitioner’s cited Ex.1031 shows a mean viscosity of 2,560 cP for agave syrup
`• Dr. Berkland could not identify any evidence from within Dr. Crowley’s Declaration
`or exhibits to support agave syrup viscosity of 212 cP (Ex.1051, 24:3-17, 47:5-
`49:18)
`• Petitioner presents to evidence to rebut that agave syrup with a mean viscosity of
`2,560 cP cannot support obviousness within FR458-Example 1 and WO742-
`Example IX because a POSA would understand the resulting formulations would
`have viscosities >1,500 cP (Ex.2009, ¶¶118-119; see POR 47, 48, 30)
`• A POSA would not have been motivated to select an agave syrup of low 212 cP
`viscosity (low quality) over a higher 2,560 cP viscosity (higher quality) agave
`syrup (Ex.2009, ¶¶120-121)
`• Dr. Crowley did not submit a reply declaration
`• Petitioner’s attorney arguments in reply cannot rebut Dr. Berkland’s declaration
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`23
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition Relies on an Incorrect Viscosity Value for Agave Syrup
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 25; see also Ex.2009, ¶¶111-113
`24
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Ex.1031: Agave Syrup Has Mean Viscosity Value of 2,560 cP
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 25; see also Ex.2009, ¶¶114-115
`25
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ex.1031 Shows Agave Syrup with a Viscosity Over 10 times more than 212 cP
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶115-117; see also POR, 25-26; Ex.1051 (Berkland Tr.), 24:3-17, 47:5-49:18
`26
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It Is Undisputed that Agave Syrup with the Reported Viscosity of 2,560 cP in
`Petitioner’s Ex.1031 Could Not Support a Finding of Obviousness
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶118; see also POR, 26-28
`27
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It Is Undisputed that Agave Syrup with the Reported Viscosity of 2,560 cP in
`Petitioner’s Ex.1031 Could Not Support a Finding of Obviousness
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶119; see also POR, 26-28
`28
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It Is Undisputed that a POSA Would Select a High Quality Agave Syrup with the
`Reported Viscosity of 2,560 cP in Petitioner’s Ex.1031 over one with 212 cP
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶121; see also Ex.2009, ¶120; POR, 25-28
`29
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Claims Should Be Upheld as Patentable Because the Petition Relied on an
`Incorrect Viscosity Value for Agave Syrup
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 28; Ex.2009, ¶114 (citing Ex.1031); see also Reply, 10, n.4 (“Exhibit 1031, which
`describes samples of agave syrup with a mean viscosity of 2,560 cP”)
`30
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup Is Not an “Old” Ingredient for
`Performing Viscosity-Control in Oral
`Pharmaceutical Syrup Formulations
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`31
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup Was Not Well-Known in the Art for Performing a Viscosity-Control
`Function
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 41; Ex.2009, ¶¶142-146
`32
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup Was Not Well-Known in the Art for Performing a Viscosity-Control
`Function
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶142; see also POR, 41
`33
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup is Not a Well-Known Staple Component of Pharmaceutical Formulations
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶144; see also POR, 42
`34
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup has Widely Variable Physicochemical Quality Properties
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶44-45; see also POR, 4-6
`35
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup is Widely Variable
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶48; see also POR, 4-6
`36
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Agave Syrup is Widely Variable
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶143; see also POR, 41
`37
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition Improperly Relies on an Obvious
`Typographical Error in the ’4666 Patent
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`38
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner Relied on an Obvious Error in Claim 11 of the ’4666 Patent
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 31-32
`39
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Crowley Relied on the Obvious Error in Claim 11 of the ’4666 Patent
`
`Ex.1003
`(Crowley Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`- Ex.2009, ¶119
`40
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Claim 11 of the ’4666 Patent Recites an Obvious Typographical Error
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 30-31; Ex.2009, ¶¶125-133
`41
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Berkland’s Testimony Demonstrating the Obvious Error in Claim 11 of the ’4666
`Patent is Unaddressed and Unrebutted by Petitioner
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶125-128; see also POR, 31-34
`42
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Berkland’s Testimony Demonstrating the Obvious Error in Claim 11 of the ’4666
`Patent is Unaddressed and Unrebutted by Petitioner
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶129-133; see also POR, 31-34
`43
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Berkland’s Declaration Demonstrating the Obvious Error in Claim 11 of the ’4666
`Patent is Unaddressed and Unrebutted by Petitioner
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶129-133; see also POR, 31-34
`44
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1 Fails to Demonstrate Obviousness of
`any Challenged Claims 1-24
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`45
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`46
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1 Fails to Demonstrate Obviousness
`
`• The Petition failed to articulate with particularity any motivation to combine FR458
`with the viscosity ranges of the ’4666 patent or WO133 (e.g., POR, 38-40; Ex.2009, ¶140)
`• The Petition failed to articulate with particularity any reasonable expectation of
`success in achieving the viscosity ranges of the ’4666 patent or WO133 (e.g., POR,
`38-40; Ex.2009, ¶140)
`• The Petition does not identify or suggest any modifications to the example
`formulations in FR458 (e.g., POR, 35-36 (n.2), 48; Ex.2009, ¶150)
`• The Petition relies on the conclusory and incorrect assertion that agave syrup
`as a viscosity of 212 cP (e.g., POR, 43-44; Ex.2009, ¶147)
`• The Petition failed to address the claims “as a whole” (e.g., POR, 51-52; Surreply, 14-15)
`• There would be no motivation or expectation of success in using agave syrup
`with 212 cP in FR458-Example 1 (e.g., Ex.2009, ¶150; POR )
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`47
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`FR458 Does Not Disclose Any Viscosity Values for Agave Syrup or Its Formulations
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 14-15; Ex.2009, ¶80
`48
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`FR458 Uses Additional Ingredients Because Formulations Based on Natural Syrups
`are Not Easy to Obtain
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 15; Ex.2009, ¶79; ID, 9; Ex.1003 (Crowley Decl., ¶64)
`49
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`FR458-Example 1: 100 mL formulation with substantial water
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 15-16; Ex.2009, ¶¶ 81-82
`50
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`FR458-Example 1: No Disclosure re Viscosity of Agave or Final Formulation
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶¶82-83; see also POR, 16-17
`51
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The ’4666 Patent: No Agave Syrup; Viscosity Range of 1000-3000 cP
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 10
`52
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`WO133: No Agave Syrup; Viscosity Range of 200-900 cP
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 10
`53
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: No Articulated Motivation or Reasonable Expectation of Success in
`Combining FR458 with The Viscosity Ranges of the ’4666 Patent or WO133
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 28-29
`54
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: No Articulated Motivation or Reasonable Expectation of Success in
`Combining FR458 with The Viscosity Ranges of the ’4666 Patent or WO133
`
`Pet. (Paper 2)
`
`The Petition did not assert with particularity any motivation or reasonable expectation of success with
`respect to combining FR458 with the specific viscosity ranges of the ’4666 patent or WO133
`-see POR, 38-40, 43-45, 47-50, 62-63; Surreply, 20-21.
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 28-29
`55
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: Petitioner’s Motivation to Combine Never Mentions Viscosity and Does Not
`Propose Any Modifications to FR458 to Achieve a Particular Viscosity
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶140; see also POR, 40
`56
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: Petitioner’s Motivation to Combine Never Mentions Viscosity and Does Not
`Propose Any Modifications to FR458 to Achieve a Particular Viscosity
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 40
`57
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: The Petition Does Present Any Proposed Modifications to the Example
`Formulations of FR458 or WO133 to Achieve a Particular Viscosity Value
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 35-36 (n.2), 48; see also Ex.2009, ¶¶150, 167
`58
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Reply (Paper 25)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Reply, 2; see also POR, 38-40,43; Ex.2009, ¶¶140, 147; Surreply (Paper 29), 20-21; Notice (Paper 27), 2-3
`59
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 20-21; Notice (Paper 27), 2-3
`60
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: The Viscosity Limitation
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`61
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition’s Assertions re the Viscosity Limitation of Claim 1 Fail to Address the
`Claims “as a whole”
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 31-32; see also POR, 43-44; Ex.2009, ¶147
`62
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition’s Assertions re the Viscosity Limitation of Claim 1 Fail to Address the
`Claims “as a whole”
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 31-32; see also POR, 43-44; Ex.2009, ¶147
`63
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It is Undisputed that a POSA Would Have Known That Using Agave Syrup with
`Viscosity of 212 cP in FR458-Example 1 Would Yield a “readily pourable” Formulation
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶150; see also POR, 47-48
`64
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition Proposed No Modifications to FR458
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶150.
`65
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Reply (Paper 25)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Reply, 11; see also POR, 35-36 (n.2), 48; Ex.2009, ¶¶150; Surreply (Paper 29), 5-10; Notice (Paper 27), 1-2
`66
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 4; Notice (Paper 27), 1-2
`67
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 7; Notice (Paper 27), 1-2
`68
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition Relied on Added Water to Achieve a Final Volume—Not a Final Desired
`Viscosity
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 15-16; Notice (Paper 27), 1-2
`69
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: Dependent Claims
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`70
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1 Fails to Demonstrate Obviousness of Dependent Claims
`
`• The Petition fails to articulate any reasoned motivation to combine or reasonable
`expectation of success with respect to the dependent claims as a whole (e.g.,
`POR, 53-56; Ex.2009, ¶¶ 154-164)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`71
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 1: Exemplary Failure to Address Dependent Claims as a Whole (Claim 9)
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 55-56; see also Ex.2009, ¶¶160-161
`72
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2 Fails to Demonstrate Obviousness of
`Challenged Claims 1-17
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`73
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`74
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2 Fails to Demonstrate Obviousness
`
`• The Petition failed to articulate with particularity any motivation to combine
`WO742 with the viscosity ranges of the ’4666 patent or WO133 (e.g., POR, 57-58;
`Ex.2009, ¶167)
`• The Petition failed to articulate with particularity any reasonable expectation of
`success in achieving the viscosity ranges of the ’4666 patent or WO133 (e.g., POR,
`58-63; Ex.2009, ¶¶ 168-171)
`• The Petition does not identify or suggest any modifications to the example
`formulations in FR458 (e.g., POR, 35-36 (n.2), 48; Ex.2009, ¶167)
`• The Petition relies on the conclusory and incorrect assertion that agave syrup
`as a viscosity of 212 cP (e.g., POR, 43-44; Ex.2009, ¶¶166-168)
`• The Petition failed to address the claims “as a whole” (e.g., Surreply, 14-15)
`• There would be no motivation or expectation of success in using agave syrup
`with 212 cP in FR458-Example 1 (e.g., Ex.2009, ¶¶ 168-171; POR 58-63; Surreply, 7-9)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`75
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`WO742 Does Not Disclose Any Viscosity Values for Agave Syrup or Its Formulations
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶104; see also POR, 18-19
`76
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`WO742-Example IX: 15 mL formulation with various constituent ingredients
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 18; see also POR, 62; Ex.2009, ¶102; Ex.1003, ¶¶64-65; Pet., 57-58 (“Example IX of WO742, which
`consists mainly of agave syrup and other ingredients”)
`77
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2 Fails for the Same Reasons as Ground 1
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶¶ 166-167; see also POR, 57-58
`78
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: No Articulated Motivation or Reasonable Expectation of Success in
`Combining WO742 with The Viscosity Ranges of the ’4666 Patent or WO133
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 54-55
`79
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: No Articulated Motivation or Reasonable Expectation of Success in
`Combining WO742 with The Viscosity Ranges of the ’4666 Patent or WO133
`
`Pet. (Paper 2)
`
`The Petition did not assert with particularity any motivation or reasonable expectation of success with
`respect to combining WO742 with the specific viscosity ranges of the ’4666 patent or WO133
`-see POR, 58.
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 54-55
`80
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: Petitioner’s Motivation to Combine Never Mentions Viscosity and Does Not
`Propose Any Modifications to FR458 to Achieve a Particular Viscosity
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 58
`81
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: The Petition Does Present Any Proposed Modifications to the Example
`Formulations of FR458 or WO133 to Achieve a Particular Viscosity Value
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 35-36, n.2
`82
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Reply (Paper 25)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Reply, 4; see also POR, 57-58; Ex.2009, ¶¶165-168; Surreply (Paper 29), 20-21; Notice (Paper 27), 2-3
`83
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Petitioner’s Improper New Attorney Arguments on Reply Further Show the Petition’s
`Failures re Motivation to Combine and Reasonable Expectation of Success
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 20-21; Notice (Paper 27), 2-3
`84
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: The Viscosity Limitation
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`85
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Petition’s Assertions re the Viscosity Limitation of Claim 1 Fail to Address the
`Claims “as a whole” (same as Ground 1)
`
`Pet. (Paper 2)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Pet. 57-58; see also POR, 58-60; Ex.2009, ¶¶ 168-171
`86
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It is Undisputed that a POSA Would Have Known That Using Agave Syrup with
`Viscosity of 212 cP in WO742-Example IX Would Be a “readily pourable” Formulation
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶168; see also POR, 61-63
`87
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`It is Undisputed that a POSA Would Have Known That Using Agave Syrup with
`Viscosity of 212 cP in WO742-Example IX Would Be a “readily pourable” Formulation
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶171; see also POR, 61-63
`88
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: Dependent Claims
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`89
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2 Fails to Demonstrate Obviousness of Dependent Claims
`
`• The Petition fails to articulate any reasoned motivation to combine or reasonable
`expectation of success with respect to the dependent claims as a whole (e.g.,
`POR, 63-68; Ex.2009, ¶¶173-179)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`90
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 2: Exemplary Failure to Address Dependent Claims as a Whole (Claim 9)
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Ex.2009, ¶178; see also POR, 66-67
`91
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Ground 3 is Moot
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`92
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Conditional Ground 3 Has Not Been Triggered and It is Moot
`
`POR (Paper 20)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-POR, 68
`93
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Conditional Ground 3 Has Not Been Triggered and It is Moot
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 1, n.1
`94
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`The Institution Decision re Ground 3
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 17-18
`95
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`All Challenged Claims Should Be Found
`Patentable
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`96
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Backup Slides
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`97
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Legal Standards
`
`•
`
`•
`
`“[T]he decision to institute and the final written decision are ‘two very different analyses,’ and each
`applies a ‘qualitatively different standard.’”
`—In re Magnum Oil Tools Int’l, Ltd., 829 F.3d 1364, 1376 (Fed. Cir. 2016)
`(quoting TriVascular, Inc. v. Samuels, 812 F.3d 1056, 1068 (Fed. Cir. 2016))
`
`“This court has provided further assurance of an ‘as a whole’ assessment of the invention under § 103 by
`requiring a showing that an artisan of ordinary skill in the art at the time of invention, confronted by the same
`problems as the inventor and with no knowledge of the claimed invention, would select the various elements
`from the prior art and combine them in the claimed manner.”
`—Ruiz v. A.B. Chance Co., 357 F.3d 1270, 1275 (Fed. Cir. 2004)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`98
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Crowley’s Declaration Teaches Away from “higher viscosity” and States a Desire
`for “readily pourable” formulations with 20-150 cP
`
`Ex.1003
`(Crowley Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`- Ex.1003, ¶59; see also Ex.2009, ¶55
`99
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Excipients in FR458 includes Agar-Agar and Xanthan Gum
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶82; POR, 15-16.
`100
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Excipients in FR458 includes Agar-Agar and Xanthan Gum
`
`Ex.2009
`(Berkland Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`--Ex.2009, ¶55; see also POR, 7-8
`101
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Berkland’s Testimony Is More Credible than Dr. Crowley’s
`
`Institution Decision
`(Paper 8)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-ID, 17-18
`102
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Berkland’s Testimony is More Reliable than Dr. Crowley’s
`
`Surreply (Paper 29)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`-Surreply, 25
`103
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Crowley’s Error Regarding the Viscosity of Agave Syrup
`
`Ex.1003
`(Crowley Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`- Ex.1003, ¶52
`104
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`
`
`Dr. Crowley’s Assertion of Water to Achieve a Final Formulation Volume
`
`Ex.1003
`(Crowley Decl.)
`
`DEMONSTRATIVE EXHIBIT – NOT EVIDENCE
`
`- Ex.1003, ¶117
`105
`
`KinderFarms v. Genexa, PGR2023-00051 - Ex. 2024
`
`